Compare · CLDX vs NTLA
CLDX vs NTLA
Side-by-side comparison of Celldex Therapeutics Inc. (CLDX) and Intellia Therapeutics Inc. (NTLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLDX and NTLA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- CLDX is the larger of the two at $2.58B, about 1.2x NTLA ($2.12B).
- Over the past year, CLDX is up 55.9% and NTLA is up 63.1% - NTLA leads by 7.2 points.
- NTLA has been more active in the news (12 items in the past 4 weeks vs 3 for CLDX).
- NTLA has more recent analyst coverage (25 ratings vs 21 for CLDX).
- Company
- Celldex Therapeutics Inc.
- Intellia Therapeutics Inc.
- Price
- $32.43-1.40%
- $15.66+2.96%
- Market cap
- $2.58B
- $2.12B
- 1M return
- +7.63%
- +31.27%
- 1Y return
- +55.91%
- +63.13%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 3
- 12
- Recent ratings
- 21
- 25
Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest CLDX
- Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
- Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
- Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
- SEC Form SCHEDULE 13G filed by Celldex Therapeutics Inc.
- SEC Form 10-Q filed by Celldex Therapeutics Inc.
- Celldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celldex Reports First Quarter Financial Results and Provides Corporate Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.
- SEC Form DEF 14A filed by Celldex Therapeutics Inc.
- Celldex Therapeutics upgraded by Barclays with a new price target
Latest NTLA
- Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Director Verwiel Frank was granted 9,200 shares, increasing direct ownership by 35% to 35,148 units (SEC Form 4)
- Director Keresty Georgia was granted 9,200 shares, increasing direct ownership by 29% to 41,083 units (SEC Form 4)
- Director Goodman Jesse was granted 9,200 shares, increasing direct ownership by 38% to 33,559 units (SEC Form 4)
- Director Goff Brian was granted 9,200 shares, increasing direct ownership by 39% to 32,609 units (SEC Form 4)
- Director Cohen Fred E was granted 9,200 shares, increasing direct ownership by 4% to 216,653 units (SEC Form 4)
- Director Chase William J was granted 9,200 shares, increasing direct ownership by 7% to 143,893 units (SEC Form 4)
- Director Bhanji Muna was granted 9,200 shares, increasing direct ownership by 34% to 36,403 units (SEC Form 4)
- Intellia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders